Clinical Trials Logo

Clinical Trial Summary

Women with symptoms of voiding dysfunction may be associated with detrusor underactivity or bladder outlet obstruction. However, the prevalence of detrusor underactivity and bladder outlet obstruction remained obscure. Thus, the aim of this study was to elucidate the prevalence of detrusor underactivity and bladder outlet obstruction in women with and without symptoms of voiding dysfunction.


Clinical Trial Description

Between February 2005 and December 2020, all women with lower urinary tract symptoms but without cystocele who visited the urogynecological department of a medical center for urodynamic evaluation were reviewed. Those women who have no complete data of maximum flow rate, voided volume, post-void residual volume and detrusor pressure at maximum flow rate were excluded from this study. Detrusor underactivity was defined when the detrusor pressure at maximum flow rate was less than 20 cmH2O, the maximum flow rate was less than 15 mL/s, and the bladder voiding efficiency was less than 90 %. Bladder outlet obstruction was defined when the the detrusor pressure at maximum flow rate was not less than 40 cmH2O, and the maximum flow rate was less than 12 mL/s. Those women without detrusor interactivity or bladder outlet obstruction were allocated to the non-DU/BOO group. STATA software was used for statistical analysis. Chi2 test, univariate and multivariable logistic regression test were used for statistical analysis as appropriate. A p < 0.05 was considered as statistically significant. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04981080
Study type Observational
Source National Taiwan University Hospital
Contact
Status Completed
Phase
Start date February 1, 2005
Completion date December 31, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT03457805 - Prostatic Artery Embolization in Advanced Prostate Cancer N/A
Completed NCT00507455 - Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction Phase 2
Recruiting NCT04626167 - Concomitant Renal and Urinary Bladder Allograft Transplantation Early Phase 1
Not yet recruiting NCT06422312 - A Study Comparing a Disposable Flexible Cystoscope With Reusable Scopes in Adult Patients. N/A
Suspended NCT01779349 - Bladder Outlet Obstruction Observation Using Dynamic Urine Vibration "Holter" N/A
Not yet recruiting NCT01388348 - Diagnosis of Bladder Outlet Obstruction Using Dynamic Urine Vibration "Holter" in Comparison to Pressure Flow Study N/A
Completed NCT00710749 - The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects N/A
Recruiting NCT03486639 - Urodynamics and Clinical Factors That Are Associated With Bladder Over-sensitivity
Enrolling by invitation NCT02869061 - Effectiveness and Safety of Adipose-derived Regenerative Cells for Reduction of Risk of Bladder Neck Contracture Phase 1/Phase 2
Active, not recruiting NCT05631080 - Transurethral Prostate Enucleation in Surveillance Protocol for Low Risk Prostate Cancer Phase 4
Completed NCT02031653 - Comparison Between Invasive Pressure Flow Study and Non-invasive Penile Cuff Test
Completed NCT00605319 - An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia Phase 4
Recruiting NCT03503721 - Bipolar Transurethral Enucleation (BipolEP) vs Bipolar Transurethral Resection of the Prostate N/A
Not yet recruiting NCT05910983 - Prostate Enucleation With Intravesical Botox Injections in Treating BPH and Bladder Overactivity N/A
Recruiting NCT03281798 - Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction N/A
Completed NCT05470751 - GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology
Completed NCT00410514 - A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO) Phase 2
Recruiting NCT06152666 - Day-case Endourology; Enablers, Barriers, Unexpected Outcomes
Not yet recruiting NCT04514718 - Low Energy HoLEP on IPSS N/A
Completed NCT01661621 - Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1 Phase 4